

WHAT IS CLAIMED IS:

1. An antibody composition comprising at least one antibody which specifically binds to at least two variants of an epitope of an HIV-1 Tat protein, said epitope located within the amino acid sequence R1-Val-Asp-Pro-Y-Leu-Glu-Pro-R2 SEQ ID NO: 36, wherein Y is selected from the group consisting of Arg, Lys, Ser and Asn, wherein R1 is a sequence of up to 5 amino acids, wherein R2 is a sequence of up to 14 additional amino acids, and each variant has a different amino acid at Y.
2. The composition according to claim 1, comprising a mixture of from one to four different said antibodies, said mixture capable of binding three different Y variants of the epitope defined by said SEQ ID NO: 36.
3. The composition according to claim 1, comprising a mixture of from one to four different said antibodies, said mixture capable of binding all four different Y variants of the epitope defined by said SEQ ID NO: 36.
4. The composition according to claim 1, further comprising an antibody to an HIV Tat-1 protein that specifically binds to an epitope located within the amino acid sequence -Lys-X-Leu-Gly-Ile-Ser-Tyr-Gly-Arg-Lys- of SEQ ID NO:37, wherein said amino acid X is Gly or Ala.
5. The composition according to claim 1, wherein each said antibody in said composition is selected from the group consisting of an isolated polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, an antibody produced by screening phage displays, and mixtures thereof.
6. A pharmaceutical composition comprising an antibody composition of claim 1 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising an antibody composition of claim 2 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising an antibody composition of claim 3 and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising an antibody composition of claim 4 and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising an antibody composition of claim 5 and a pharmaceutically acceptable carrier.

10085523.022802